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INTRODUCTION
Even after the introduction of rocuro-
nium (R) into clinical practice, a major focus
of research with neuromuscular blocking
agents had been the achievement of rapid
onset of muscle relaxation using nondepo-
larizing agents, without undue prolonga-
tion of clinical duration or deleterious
hemodynamic side-effects. It has long
been appreciated that onset of neuromus-
cular block can be accelerated by increas-
ing the dose of relaxant [1, 2]. However,
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Purpose: The present study was undertaken to evaluate onset, and early and late recov-
ery of neuromuscular block after a combination of mivacurium (M) and rocuronium (R).
Methods: In this controlled, randomized study, 45 consenting ASA I-II patients were
assigned to one of three treatment groups: 2•ED95 R alone (2R); 2•ED95 R plus 1•ED95 M
(2R1M); or 2•ED95 R plus 2•ED95 M (2R2M). Neuromuscular monitoring of the ulnar nerve
consisted of surface electrode stimulation and force transduction of the adductor pollicis
muscle. Stable baseline stimulation (1 Hz, square-wave, supramaximal current) was estab-
lished prior to relaxant administration and continued until 95 percent twitch height depres-
sion (onset). Thereafter, train-of-four stimulation every 10 seconds was used to record
recovery data until 95 percent recovery (T95%). Data were analyzed using grouped t-tests, 
ANOVA, and Newman-Keuls multiple comparison tests. Significance was defined at the
p < 0.05 level. Results: The addition of mivacurium to rocuronium did not accelerate onset
of block. The combination prolonged the clinical duration (time to 5 percent recovery, T5%), 
but did not affect subsequent recovery parameters: T5% in the 2R1M and 2R2M groups 
were 100 percent and 118 percent longer than in the 2R group, respectively (p < 0.05); 
the T5-25% (early recovery) and T25-75% (linear recovery) indexes were similar in all three 
groups. Conclusions: The present study did not note an acceleration of block onset 
when mivacurium was added to rocuronium. The findings suggest that the addition of 
mivacurium (1-2•ED95) to rocuronium (2•ED95) prolongs the clinical duration of the
longer-acting agent, rocuronium, but has no effect on the early or linear recovery indexes
of rocuronium. Thus, although clinical duration is prolonged, recovery from the combina-
tion regimens proceeds as if no mivacurium had been added to rocuronium.high-dose therapy is associated with an
increase in the frequency of unwanted
side-effects, such as prolongation of block
[3] and/or histamine release [4]. The intro-
duction of rocuronium into clinical prac-
tice has enabled more rapid attainment of
block using doses that minimize these
unwanted side-effects. However, in most
cases, it is difficult to achieve the rapid
onset (and, equally important, the reliable
muscle relaxation) that can be obtained
with succinylcholine when one uses doses
of rocuronium that do not cause prolonged
block [5]. 
Several investigators have shown that
nondepolarizing relaxants often work syn-
ergistically and that when drugs possess-
ing different side-effect profiles are com-
bined, they can achieve the desired effect
without exacerbating individual drug side
effects. Stout and collaborators [6] showed
that the combination of mivacurium (M)
and vecuronium provided a favorable pro-
file with respect to onset and duration of
block when compared to vecuronium
alone. Naguib [7] and Stevens and col-
leagues [8] have demonstrated that the
combination of mivacurium plus rocuroni-
um could be of value for patients requiring
rapid onset of intubating conditions for
surgeries of relatively brief durations. The
effects of the drug combination on the
duration of action and recovery indices,
however, were less clear.
The present study was undertaken to
evaluate the effect of combining mivacuri-
um with rocuronium, and specifically to
evaluate block onset time (time from drug
administration until decrease of the first
twitch of the train-of-four [T1] to 5 percent
of baseline), the clinical duration (time
from drug administration until recovery of
T1 to 5 percent of baseline twitch), the
early recovery index (T5-25%), and the
linear recovery index (T25-75%).  We
evaluated recovery before and after 5 per-
cent recovery of the first T1, since this is
the time when decisions are made with
respect to either supplementing the neuro-
muscular block or planning to administer
reversal agents. In such a context, it would
be important to know if neuromuscular
recovery would proceed as if rocuronium
had been given alone, or whether its
recovery profile would be affected by a
persistent effect of the added mivacurium.
We hypothesized that the addition of
mivacurium to rocuronium would acceler-
ate the onset of neuromuscular block in
proportion to the ED95 equivalents admin-
istered. Moreover, this acceleration of
onset should be accomplished without
undue prolongation of rocuronium, since
recovery from mivacurium is much faster
than that from rocuronium, and each drug
possesses a different mode of metabolism.
METHODS
With Institutional Review Board
approval, informed written consent was
obtained from 45 patients who were then
randomly assigned to one of three treat-
ment groups: 1) R 0.6 mg•kg-1 alone
(2•ED95 R, [2R]); 2) R 0.6 mg•kg-1 plus M
0.07 mg•kg-1 (2•ED95 R plus 1•ED95 M,
[2R1M]); or 3) R 0.6 mg•kg-1 plus M 0.15
mg•kg-1 (2•ED95 of each drug, [2R2M]).
All patients were ASAPhysical Status I-II,
18 to 70 years of age, and within 25 per-
cent of ideal body weight; none had any
physical condition or had received any
medications known to interfere with neu-
romuscular transmission. Halogenated
anesthetic agents were avoided. 
Anesthesia was induced with thiopen-
tal 2-4 mg•kg-1 or propofol 1-2 mg•kg-1,
midazolam 0.03 mg•kg-1, fentanyl 2-5
µg•kg-1 and was maintained with 70 per-
cent N2O in oxygen (O2) plus supplemen-
tal fentanyl and/or propofol as required.
End-tidal carbon dioxide concentration
(ETCO2), O2 saturation, non-invasive
blood pressure, heart rate, and temperature
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ical physiologic ranges throughout the
study. Neuromuscular monitoring of the
ulnar nerve consisted of neurostimulation
via surface electrodes at the wrist and
force transduction monitoring of the
adductor pollicis muscle. 
Data were recorded by an interfaced
computer that provided a resolution for
individual twitch responses of 2 mmHg.
After induction of anesthesia and estab-
lishment of adequate mask ventilation, the
randomly assigned relaxant regimen was
administered by IV bolus over a 3-second
period. Stable baseline stimulation (1 Hz,
square-wave, supramaximal current) was
established for 10 minutes prior to relaxant
administration, and was continued until 95
percent twitch height depression (defined
as block onset). Thereafter, train-of-four
stimulation every 10 seconds was used to
record recovery data, where the relative
height of the first T1 was compared to the
pre-relaxant control T1 value and was
recorded at 10-second intervals until 5 per-
cent, 25 percent, 75 percent and 95 percent
recovery (T5%, T25%, T25% and T95%, res-
pectively). Data were analyzed using
grouped t-tests, analysis of variance
(ANOVA), and Newman-Keuls multiple
comparison tests with corrections for mul-
tiple comparisons. Statistical significance
was defined as p < 0.05.
RESULTS
The patients in the three treatment
groups were similar with respect to age,
height, weight, and gender distribution.
The data obtained for onset and recovery
are listed in Table 1. The addition of either
1•ED95 or 2•ED95 of mivacurium to
rocuronium did not accelerate onset.
However, both combination regimens
demonstrated that the addition of mivac-
urium to rocuronium prolonged the time to
5 percent recovery (T5%), but did not
affect recovery thereafter: T5% in the
2R1M and 2R2M groups were 100 percent
and 118 percent longer than in the 2R
group, respectively (p < 0.05); the T5-25%
and T25-75% recovery indexes were
similar in all three groups (Table 2).
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Table 1. Times to Onset and Early and Late Recovery (Mean ± SD).
Group Onset (min)   T5% (min)   T25% (min)   T75% (min)   T95% (min)
2R 0.8 ± 0.2 21.9 ± 8 27.6 ± 9 36.1 ± 14 40.6 ± 16
2R1M 1.0 ± 0.3 43.8 ± 8* 51.0 ± 10* 62.8 ± 12* 66.9 ± 13*
2R2M 0.9 ± 0.2 47.8 ± 13* 55.0 ± 16* 66.7 ± 22* 75.5 ± 28*
*p < 0.05 vs. Group 2R values (ANOVA with Bonferroni adjustment for multiple comp-
isons).  R, rocuronium; M, mivacurium; T, time to recovery
Table 2. Early and Linear Recovery Indexes ( Mean ± SD).
Group    T5-25% (min) P   T25-75% (min) P
2R 5.7 ± 3 8.5 ± 6
2R1M 6.2 ± 3 P=  N S 11.5 ± 4 P=  N S
2R2M 7.3 ± 4 P=  N S 11.7 ± 7 P=  N S
R, rocuronium; M, mivacurium; T, time to recovery.DISCUSSION
Recent advances in the pharmacology
of muscle relaxants have resulted in the
availability of an unprecedented number
of drugs. Their development has been
spurred, no doubt, by the quest for the
“perfect” muscle relaxant, one that has the
rapid and reliable onset of succinylcholine
without any of its untoward side-effects.
To date, no nondepolarizing muscle block-
er (NMB) developed for clinical use
achieves this ideal profile. Hence, clini-
cians have taken other approaches to
achieving the rapid onset of succinyl-
choline. 
Two of the most popular methods are
large-dose (greater than 3-4•ED95) NMB
therapy and combination therapy. While
large doses of NMBs may achieve the goal
of rapid onset, their use is limited by two
undesirable effects. In the case of steroidal
derivatives, which depend on organ elimi-
nation, prolongation of block may be
problematic when large doses are used [3].
With large doses of agents with organ-
independent elimination, such as the ben-
zylisoquinolinium compounds, clinically
significant histamine release may occur
[4]. Combination NMB therapy has been
developed in an attempt to solve the short-
comings associated with large-dose single-
agent therapy: normal doses (i.e., doses
that are not usually associated with sys-
temic side effects) of steroidal and ben-
zylisoquinolinium compounds may be
combined to achieve a large total drug
dose and hasten onset, without producing
the undesirable effects of large doses of
either of the two individual NMBs. 
Vecuronium and mivacurium have
been used for this purpose with some
degree of success [6]. More recently,
rocuronium has been used in combination
therapy [7, 8]. By administering it with
mivacurium, we attempted to exploit the
advantages of each drug: rocuronium's
rapid onset and mivacurium's organ-inde-
pendent elimination and short duration of
action. The interaction between rocuroni-
um and mivacurium has been shown to be
synergistic with regard to potency, with
the ED50 of the mixture being only 62 per-
cent of the predicted value based on a
purely additive interaction [7]. 
On initial examination, the most sur-
prising finding of the current investigation
was that onset times were similar for all
three groups. The present study did not
note the acceleration of onset that was
associated with combinations of mivacuri-
um plus vecuronium and mivacurium plus
rocuronium in previous studies [6, 7-11].
This may be attributable to multiple fac-
tors: 1) the more rapid apparent onset of
block associated with stimulation at 1 Hz
(as in our current study), a rate that has
been shown to accelerate onset [12]; 2) the
potential additive effect of mivacurium
may have been overshadowed not only by
the relatively rapid rate of stimulation, but
also by the time required for circulation of
the drug and its delivery to the biophase;
and 3) the concept of molecular load. The
time of onset of NMB is directly propor-
tional to the number of molecules that are
delivered to the biophase. Acceleration of
onset can be achieved by administration of
a large total dose, a drug with low plasma
protein binding (that leaves more unbound
drug available), or a drug with low poten-
cy [13]. In the case of a drug with low
potency, for any specific ED95 multiple, a
greater total number of (less potent) mole-
cules are administered, leading to faster
occupancy of the requisite number of post-
synaptic receptors (and thus, faster onset of
block). Potency thus partially accounts for
the slow onset of highly potent doxacuri-
um, for the intermediate onset duration of
the moderately potent mivacurium and
vecuronium, and for the relatively fast
onset of the least potent agent, rocuroni-
um. Thus, adding 1•ED95 M to 1•ED95 R
(i.e., doubling the ED95% administered)
increases the total number of molecules by
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urium's contribution to the total number of
free NMB molecules is even less, since
rocuronium is not highly bound to plasma
proteins.
Other investigations of combination
therapy recovery profiles have had limita-
tions. One study only assessed the tradi-
tional recovery index between 25 percent
and 75 percent of baseline [7], while
another examined only early recovery,
between 10 to 25 percent [6]. High resolu-
tion monitoring employed during our
study facilitated delineation of early
recovery, thereby enabling us to document
that the addition to rocuronium of 1 and
2•ED95 of mivacurium prolonged T5%
recovery by 22 and 26 minutes, respec-
tively, but did not cause further prolonga-
tion of recovery; thus, recovery after T5%
proceeds as if 2•ED95 rocuronium
alone had been administered. This is con-
sistent with mivacurium's brief duration of
action [14], and indicates that after attain-
ment of T5%, subsequent recovery from
(and probably reversal of) neuromuscular
block should proceed as if the patient
received 2•ED95 of rocuronium alone. The
consistency of linear recovery (RI25-75%)
in our study is consistent with that report-
ed previously; similar results were report-
ed by Naguib and colleagues [7, 11] and
Fletcher and colleagues [10] who found
that the addition of mivacurium to rocuro-
nium did not change the linear recovery
index significantly.
CONCLUSION
This study showed that the addition of
mivacurium to rocuronium did not acceler-
ate onset of neuromuscular block, but did
prolong the T5% recovery without
affecting subsequent (linear) recovery
index. Our study also expands upon other
investigations that have failed to show a
clear dose/response relationship between
onset times and combination ED95 multi-
ples (mivacurium plus rocuronium). If clin-
icians choose combination therapy with
mivacurium plus rocuronium to achieve
prolongation of relaxation while avoiding
class-specific side effects, they can expect
that, once T5% has been attained, recovery
should proceed normally.
We conclude that when 2•ED95 of
mivacurium is administered in combina-
tion with a 2•ED95 dose of a longer acting
agent (e.g., rocuronium), in the absence of
atypical block prolongation (due to
pseudocholinesterase deficiency), then
recovery beyond T5% should proceed as
if 2•ED95 of the longer-acting agent had
been administered alone. While we antici-
pate that pharmacologic reversal likewise
would resemble that after 2•ED95 of the
longer acting agent, this remains to be
confirmed.
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